News MSD adds bispecific cancer antibody via $1.3bn Curon deal MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies.
Deep Dive Moving from autologous to allogeneic ACT paradigms We have come so far in a relatively short time with Adoptive Cellular Transfer (ACT).
News Aspen, Bambusa close IPOs as Corxel takes SPAC route Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
